亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients

阿帕蒂尼 医学 内科学 结直肠癌 肿瘤科 癌症 胃肠病学
作者
Dengdeng Pan,Dongliang Liu,Lichuan Liang,Tongyi Shen,Chenzhang Shi,Huanlong Qin
出处
期刊:Frontiers in Oncology [Frontiers Media]
卷期号:12: 863392-863392 被引量:5
标识
DOI:10.3389/fonc.2022.863392
摘要

Purpose Programmed cell death protein 1 (PD-1) inhibitor plus apatinib is reported to be a promising strategy for advanced cancers. Moreover, a PD-1 inhibitor or apatinib exerts a certain efficacy in advanced colorectal cancer (CRC), whereas their synergistic effect is unclear. This study aimed to evaluate the treatment efficacy and safety of a PD-1 inhibitor plus apatinib in advanced CRC patients. Methods In total, 45 advanced CRC patients who received a PD-1 inhibitor plus apatinib (PD-1 inhibitor plus apatinib group, N=20) or apatinib monotherapy (apatinib group, N=25) as third-line therapies were enrolled in the current study. Results The objective response rate (20.0% vs. 8.0%) (P=0.383) and disease control rate (70.0% vs. 52.0%) (P=0.221) were numerically increased in the PD-1 inhibitor plus apatinib group, respectively, compared with the apatinib group, but no statistical significance was observed. The median progression-free survival (PFS) was 7.5 versus 4.8 months; the 1-year PFS rate was 32.5% versus 9.9%; the median overall survival (OS) was 12.3 versus 8.7 months; and the 1-year OS rate was 50.7% versus 27.0% in the PD-1 inhibitor plus apatinib group versus the apatinib group, respectively. PFS (P=0.038) and OS (P=0.048) were prolonged in the PD-1 inhibitor plus apatinib group compared with the apatinib group. PD-1 inhibitor plus apatinib (versus apatinib) was independently associated with longer PFS (P=0.012) and OS (P=0.009). The majority of the adverse events were of grade 1-2, wherein the incidence was similar between groups, except for the fact that the incidence of capillary proliferation was elevated in the PD-1 inhibitor plus apatinib group compared with the apatinib group (25.5% versus 0.0%) (P=0.013). Conclusion PD-1 inhibitor plus apatinib presents a potential improvement in efficacy and survival benefit compared with apatinib monotherapy, with tolerable safety in advanced CRC patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
万能图书馆的应助被吐司采纳,获得10
3秒前
海洋球发布了新的文献求助10
4秒前
dolabmu完成签到 ,获得积分10
6秒前
魔幻雅柔完成签到,获得积分10
7秒前
月亮打烊完成签到 ,获得积分10
10秒前
文静楷瑞完成签到,获得积分10
13秒前
fx完成签到 ,获得积分10
15秒前
15秒前
fantasy的应助被十三采纳,获得10
16秒前
深情安青的应助被outlast采纳,获得10
21秒前
十三完成签到,获得积分10
22秒前
23秒前
27秒前
拼搏问薇完成签到 ,获得积分10
28秒前
29秒前
Abcqqq完成签到 ,获得积分10
29秒前
海洋球完成签到,获得积分10
31秒前
ll完成签到,获得积分20
31秒前
小蘑菇的应助被xx2026采纳,获得10
32秒前
33秒前
kxz完成签到 ,获得积分10
33秒前
34秒前
gale发布了新的文献求助10
37秒前
红墨发布了新的文献求助30
38秒前
40秒前
怕黑的驳完成签到,获得积分10
41秒前
43秒前
44秒前
45秒前
46秒前
吐司发布了新的文献求助10
47秒前
冷静新烟完成签到,获得积分10
47秒前
gale完成签到,获得积分10
50秒前
55秒前
55秒前
TIDUS完成签到,获得积分10
57秒前
独特的念柏完成签到,获得积分10
1分钟前
sadascaqwqw发布了新的文献求助10
1分钟前
36hours完成签到,获得积分10
1分钟前
田様的应助被冷静新烟采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195004
求助须知:如何正确求助?哪些是违规求助? 9580729
关于积分的说明 21872554
捐赠科研通 7794720
什么是DOI,文献DOI怎么找? 3437836
关于科研通互助平台的介绍 2561159
邀请新用户注册赠送积分活动 2484541